Denileukin Diftitox-Cxdl
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Denileukin diftitox (Lymphir) for cutaneous T-cell lymphoma.
Journal: The Medical letter on drugs and therapeutics
Published: May 02, 2026
Denileukin diftitox (Lymphir) for cutaneous T-cell lymphoma.
Journal: The Medical letter on drugs and therapeutics
Published: February 06, 2026
Safety and Effectiveness of Denileukin Diftitox-cxdl in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma: An All-Case Post-Marketing Study in Japan.
Journal: Cancer reports (Hoboken, N.J.)
Published: January 06, 2026
Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.
Journal: American journal of clinical dermatology
Published: December 01, 2025
Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need.
Journal: Expert opinion on pharmacotherapy
Published: May 08, 2025
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 19, 2024
Showing 1-6 of 6
Last Updated: 09/26/2026